



PRESS RELEASE

May 17, 2022

Watch CEO Jan Nilsson's presentation at Aktiedagen Göteborg

On Monday May 16, 2022, CEO Jan Nilsson presented at Aktiedagen in Göteborg. In his presentation, Jan talks about the company's two projects, the epilepsy project CG01, which is being developed together with Spark Therapeutics, and the lipodystrophy project CGT2. Jan also addresses CombiGene's business development and ambitions to find additional gene therapy projects with high potential for value creation within CombiGene. (Please observe that the presentation is held in Swedish.)

Information

Link: <https://www.youtube.com/watch?v=BDvmFdrOMsc>

About CombiGene AB

CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to preclinical/clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations.

The Company has signed an exclusive collaboration and licensing agreement for CombiGene's CG01 project with Spark Therapeutics.

The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.

CombiGene AB (publ)

Jan Nilsson, CEO

Tel: +46 (0)704 66 31 63

jan.nilsson@combigene.com

Please read "Ingeneious", a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. INGENEIOUS and press releases are available at www.combigene.com